NCT03422614 Pathophysiology of Inborn Immunodeficiencies
| NCT ID | NCT03422614 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Zurich |
| Condition | Primary Immune Deficiency Disorder |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2015-03-01 |
| Primary Completion | 2033-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2015-03-01 with a primary completion date of 2033-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The pathophysiology of primary immunodeficiencies (PID), which encompass a broad range of different diseases with susceptibility to infection and/or a deregulated inflammatory response, is poorly understood. Available treatments are often not specific for a distinct target and might be associated with side effects. To elucidate pathophysiology of different PIDs, stool, urine, blood, tissue biopsies and/or bone marrow will be collected and analysed for anti-microbial activity and inflammatory response. In a second step, targeted treatment for different PIDs might be developed preclinically and ex vivo according to underlying pathophysiology.
Eligibility Criteria
Inclusion Criteria: * Clinical diagnosis of an inborn error of immunity (primary immunodeficiency, PID) * Clinically healthy (non-age matched) volunteer Exclusion Criteria: * exclusion of an inborn error of immunity * secondary immunodeficiency * refusal to enter the study
Contact & Investigator
Janine Reichenbach, Prof. Dr.
PRINCIPAL INVESTIGATOR
University Children's Hospital, Zurich
Frequently Asked Questions
Who can join the NCT03422614 clinical trial?
This trial is open to participants of all sexes, studying Primary Immune Deficiency Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03422614 currently recruiting?
Yes, NCT03422614 is actively recruiting participants. Contact the research team at janine.reichenbach@kispi.uzh.ch for enrollment information.
Where is the NCT03422614 trial being conducted?
This trial is being conducted at Zurich, Switzerland.
Who is sponsoring the NCT03422614 clinical trial?
NCT03422614 is sponsored by University of Zurich. The principal investigator is Janine Reichenbach, Prof. Dr. at University Children's Hospital, Zurich. The trial plans to enroll 300 participants.